SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.041
NA - Nord America 1.009
EU - Europa 295
SA - Sud America 262
AF - Africa 35
Totale 2.642
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 956
SG - Singapore 492
BR - Brasile 214
CN - Cina 208
HK - Hong Kong 155
IT - Italia 105
VN - Vietnam 105
DE - Germania 65
MX - Messico 38
ZA - Sudafrica 30
RU - Federazione Russa 25
AR - Argentina 24
UA - Ucraina 23
ID - Indonesia 21
GB - Regno Unito 19
FI - Finlandia 17
BD - Bangladesh 15
IN - India 12
EC - Ecuador 9
CA - Canada 8
NL - Olanda 8
AT - Austria 5
ES - Italia 5
FR - Francia 5
TR - Turchia 4
VE - Venezuela 4
CO - Colombia 3
IE - Irlanda 3
IQ - Iraq 3
JP - Giappone 3
PH - Filippine 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
CH - Svizzera 2
KH - Cambogia 2
LT - Lituania 2
NP - Nepal 2
PA - Panama 2
TW - Taiwan 2
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
EE - Estonia 1
EG - Egitto 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SA - Arabia Saudita 1
SE - Svezia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 2.642
Salva come PNG Salva come JPEG
Città #
Santa Clara 417
Singapore 243
Hong Kong 155
Ashburn 73
Beijing 42
Ho Chi Minh City 42
Mexico City 34
Bologna 24
Los Angeles 24
Jakarta 18
Fairfield 17
Hanoi 17
Hefei 17
New York 17
São Paulo 17
Chicago 15
Lappeenranta 15
Dallas 14
Cambridge 13
Milan 12
Munich 11
Salt Lake City 9
Brooklyn 8
Ferrara 8
London 8
Elk Grove Village 7
Rio de Janeiro 7
Buffalo 6
Dhaka 6
Falkenstein 6
Woodbridge 6
City of London 5
Curitiba 5
Forest City 5
Fortaleza 5
Johannesburg 5
Orem 5
Rome 5
San Francisco 5
Thái Bình 5
Assago 4
Atlanta 4
Bình Dương 4
Chennai 4
Council Bluffs 4
Da Nang 4
Guayaquil 4
Houston 4
Montreal 4
Nuremberg 4
Palermo 4
Salvador 4
Seattle 4
Ankara 3
Brasília 3
Campinas 3
Denver 3
Frankfurt am Main 3
Frattamaggiore 3
Guarulhos 3
Las Vegas 3
Macaé 3
Manila 3
Montevideo 3
Moscow 3
Pelotas 3
Phoenix 3
Porto Alegre 3
Praia Grande 3
Rancho Palos Verdes 3
Sorocaba 3
Sterling 3
Tokyo 3
Americana 2
Ann Arbor 2
Anápolis 2
Arapongas 2
Arezzo 2
Baku 2
Bari 2
Belém 2
Boardman 2
Boston 2
Brescia 2
Carapicuíba 2
Careri 2
Caxias do Sul 2
Charlotte 2
Cà Mau 2
Dublin 2
Fort Worth 2
Ha Long 2
Haiphong 2
Hurlingham 2
Imola 2
Indaiatuba 2
Itabira 2
Itajaí 2
Lages 2
Manaus 2
Totale 1.519
Salva come PNG Salva come JPEG
Nome #
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 106
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 90
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 66
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 52
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 49
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 49
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 48
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 48
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 47
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 46
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 46
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 45
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 45
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 43
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 42
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 42
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 41
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 41
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 41
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 41
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 41
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 40
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 40
A headlight on liquid biopsies: a challenging tool for breast cancer management 39
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 39
Anti-endothelin drugs in solid tumors 38
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 38
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 38
Bortezomib: A new pro-apoptotic agent in cancer treatment 38
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 37
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 37
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 37
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 36
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 36
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 35
The application of cancer stem cell model in malignant mesothelioma 35
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 34
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 33
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 33
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 33
Cancer and the microbiome: Potential applications as new tumor biomarker 30
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 30
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 24
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 23
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 20
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 19
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 19
What to look for in cell-free DNA from breast cancer patients 19
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 19
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 18
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 18
Multisciplinary management of patients with liver metastasis from colorectal cancer 17
Targeted therapies in hepatocellular carcinoma 17
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 17
Well-being among Italian medical oncologists: An exploratory study 17
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 16
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 16
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 16
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 16
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 16
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 16
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 16
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 16
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 15
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 15
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 15
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 15
Ramucirumab and its use in gastric cancer treatment 15
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 15
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 14
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 14
The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: Can it really help? 13
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 13
Monoclonal antibodies in gastrointestinal cancers 13
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 13
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 13
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 13
Sex steroids, carcinogenesis, and cancer progression 13
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 13
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 12
How much of familial breast cancer risk is currently explained by the known genes? 12
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 12
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 12
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 12
Dietary restriction: could it be considered as speed bump on tumor progression road? 12
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 12
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 12
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 12
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 12
New generation anaplastic lymphoma kinase inhibitors 11
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 11
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 11
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 11
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 11
Fully human antibodies for malignant pleural mesothelioma targeting 11
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 11
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 11
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 11
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 11
TMB in NSCLC: A Broken Dream? 10
Totale 2.662
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.443
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.443
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 3 0 2 3 2 1 0
2021/202214 2 0 5 0 2 0 0 0 1 0 2 2
2022/20235 1 0 1 0 1 0 0 0 0 0 1 1
2023/2024177 0 0 0 3 1 3 1 4 22 7 11 125
2024/20251.303 40 104 41 19 212 250 21 46 101 246 107 116
2025/20261.267 180 137 239 240 435 36 0 0 0 0 0 0
Totale 2.818